MAIN STORY
When authorization does not mean access
On July 2, 2025, the FDA granted sunvozertinib accelerated approval. The decision reflected encouraging trial results, yet patients and clinicians still needed a dependable commercial route to obtain the medicine. The South China Morning Post reported that Americans traveled to China during the delay. Their journeys reveal a distinction often overlooked in discussions of medical breakthroughs: authorization and access are separate achievements.
Max Doppelt, an advocate who links patients with clinical trials, described traveling to Shanghai after his mother’s lung cancer spread to her brain. His account conveys the urgency families can experience when they feel time is running short, but it should not be mistaken for controlled evidence that a drug will work similarly for every person.
Precision medicine for a defined mutation
Zegfrovy is not a general lung cancer treatment. The FDA indication covers adults with locally advanced or metastatic non-small cell lung cancer carrying a confirmed EGFR exon 20 insertion mutation, whose disease progressed on or after platinum-based chemotherapy.















